BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30682180)

  • 1. Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study.
    Shili-Masmoudi S; Sogni P; de Ledinghen V; Esterle L; Valantin MA; Poizot-Martin I; Simon A; Rosenthal E; Lacombe K; Pialoux G; Bouchaud O; Gervais-Hasenknoff A; Goujard C; Piroth L; Zucman D; Dominguez S; Raffi F; Alric L; Bani-Sadr F; Lascoux-Combe C; Garipuy D; Miailhes P; Vittecoq D; Duvivier C; Aumaître H; Neau D; Morlat P; Dabis F; Salmon D; Wittkop L;
    PLoS One; 2019; 14(1):e0211286. PubMed ID: 30682180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.
    ANRS CO13 HEPAVIH Cohort
    AIDS; 2015 Sep; 29(14):1821-30. PubMed ID: 26372388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
    Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
    J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated Fatty Liver Index as a Risk Factor for All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study).
    Barré T; Protopopescu C; Bani-Sadr F; Piroth L; Rojas Rojas T; Salmon-Ceron D; Wittkop L; Esterle L; Sogni P; Lacombe K; Chas J; Zaegel O; Chaix ML; Miailhes P; Serfaty L; Marcellin F; Carrieri MP;
    Hepatology; 2020 Apr; 71(4):1182-1197. PubMed ID: 31466125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection.
    Malin JJ; Boesecke C; Schwarze-Zander C; Wasmuth JC; Schlabe S; Trebicka J; Spengler U; Llibre JM; Jou T; Vasylyev M; Clotet B; Rockstroh JK
    HIV Med; 2019 Mar; 20(3):230-236. PubMed ID: 30687989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
    Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J
    J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With Cirrhosis.
    John BV; Dang Y; Kaplan DE; Jou JH; Taddei TH; Spector SA; Martin P; Bastaich DR; Chao HH; Dahman B
    Clin Gastroenterol Hepatol; 2024 Apr; 22(4):778-788.e7. PubMed ID: 38061410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of direct-acting agents for hepatitis C and liver stiffness changing after sustained virological response.
    Fernandes FF; Piedade J; Guimaraes L; Nunes EP; Chaves U; Goldenzon RV; Cardoso SW; Duarte J; Grinsztejn B; Veloso VG; Pereira G; Perazzo H
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2187-2195. PubMed ID: 31062880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.
    Piroth L; Wittkop L; Lacombe K; Rosenthal E; Gilbert C; Miailhes P; Carrieri P; Chas J; Poizot-Martin I; Gervais A; Dominguez S; Neau D; Zucman D; Billaud E; Morlat P; Aumaitre H; Lascoux-Combe C; Simon A; Bouchaud O; Teicher E; Bani-Sadr F; Alric L; Vittecoq D; Boué F; Duvivier C; Valantin MA; Esterle L; Dabis F; Sogni P; Salmon D;
    J Hepatol; 2017 Jul; 67(1):23-31. PubMed ID: 28235612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
    Navarro J; Laguno M; Vilchez HH; Guardiola JM; Carrion JA; Force L; Cairó M; Cifuentes C; Vilaró J; Cucurull J; Marco A; Roget M; Erice E; Crespo M;
    J Antimicrob Chemother; 2017 Oct; 72(10):2850-2856. PubMed ID: 29091196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)-coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) HEPAVIH CO13 cohort].
    Michel L; Lions C; Winnock M; Lang JP; Loko MA; Rosenthal E; Marchou B; Valantin MA; Morlat P; Roux P; Sogni P; Spire B; Poizot-Martin I; Lacombe K; Lascoux-Combe C; Duvivier C; Neau D; Dabis F; Salmon-Ceron D; Carrieri MP;
    HIV Med; 2016 Nov; 17(10):758-765. PubMed ID: 27187027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.
    Gonzalez FA; Van den Eynde E; Perez-Hoyos S; Navarro J; Curran A; Burgos J; Falcó V; Ocaña I; Ribera E; Crespo M
    HIV Med; 2015 Apr; 16(4):211-8. PubMed ID: 25234826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients.
    Macías J; Camacho A; Von Wichmann MA; López-Cortés LF; Ortega E; Tural C; Ríos MJ; Merino D; Téllez F; Márquez M; Mancebo M; Pineda JA
    AIDS; 2013 Oct; 27(16):2541-9. PubMed ID: 23736148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin.
    Macías J; del Valle J; Rivero A; Mira JA; Camacho A; Merchante N; Pérez-Camacho I; Neukam K; Rivero-Juárez A; Mata R; Torre-Cisneros J; Pineda JA;
    J Antimicrob Chemother; 2010 Oct; 65(10):2204-11. PubMed ID: 20656678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes.
    Piedade J; Pereira G; Guimarães L; Duarte J; Victor L; Baldin C; Inacio C; Santos R; Chaves Ú; Nunes EP; Grinsztejn B; Veloso VG; Fernandes F; Perazzo H
    Sci Rep; 2021 Jun; 11(1):11681. PubMed ID: 34083617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants.
    Chalouni M; Wittkop L; Bani-Sadr F; Lacombe K; Esterle L; Gilbert C; Miailhes P; Zucman D; Valantin MA; Brégigeon-Ronot S; Morlat P; Billaud E; Piroth L; Naqvi A; Sogni P; Salmon D;
    HIV Med; 2021 Oct; 22(9):791-804. PubMed ID: 34212476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients.
    Carrieri MP; Protopopescu C; Marcellin F; Rosellini S; Wittkop L; Esterle L; Zucman D; Raffi F; Rosenthal E; Poizot-Martin I; Salmon-Ceron D; Dabis F; Spire B;
    J Hepatol; 2017 Dec; 67(6):1157-1167. PubMed ID: 28942916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Markers of HIV Infection on Change in Liver Stiffness in People With HIV and Hepatitis C Virus Co-infection After Treatment and Cure of Hepatitis C.
    van Santen DK; Agius PA; Sasadeusz J; Fairley CK; Sievert W; Gane E; Iser D; O'Reilly M; Medland NA; Moore R; Hellard ME; Hoy JF; Doyle JS;
    J Acquir Immune Defic Syndr; 2020 Dec; 85(5):e81-e89. PubMed ID: 32842055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
    Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
    Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
    Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.